Radical Prostatectomy for PSA ≥ 100 ng/ml Prostate Cancer

European Urology

Volumn 54, Issue 4, 2008, Pages 957-958

  Gontero, P ^a   Joniau, S ^b   Van Poppel, H ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BONE METASTASIS; CANCER SURVIVAL; HUMAN; LETTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 50849099162     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.03.110     Document Type: Letter

References (5)

1. Van Poppel H., and Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 53 (2008) 253-259
2. Zwergel U., Suttmann H., Schroeder T., et al. Outcome of prostate cancer patients with initial PSA ≥ 20 ng/ml undergoing radical prostatectomy. Eur Urol 52 (2007) 1058-1066
3. Lorente J.A., Morote J., Raventos C., Encabo G., and Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155 (1996) 1348-1351
4. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., and Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47 (2006) 287-297
5. Swanson G., Thompson I., Basler J., and Crawford ED. Metastatic prostate cancer-does treatment of the primary tumor matter?. J Urol 176 (2006) 1292-1298